Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
How did NRSN's recent EPS compare to expectations?
The most recent EPS for Neurosense Therapeutics Ltd is $, expectations of $-0.1.
How did Neurosense Therapeutics Ltd NRSN's revenue perform in the last quarter?
Neurosense Therapeutics Ltd revenue for the last quarter is $
What is the revenue estimate for Neurosense Therapeutics Ltd?
According to 4 of Wall street analyst, the revenue estimate of Neurosense Therapeutics Ltd range from $562.79K to $0.0
What's the earning quality score for Neurosense Therapeutics Ltd?
Neurosense Therapeutics Ltd has a earning quality score of B+/44.294106. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Neurosense Therapeutics Ltd report earnings?
Neurosense Therapeutics Ltd next earnings report is expected in 2026-06-29
What are Neurosense Therapeutics Ltd's expected earnings?
Neurosense Therapeutics Ltd expected earnings is $0.0, according to wall-street analysts.
Did Neurosense Therapeutics Ltd beat earnings expectations?
Neurosense Therapeutics Ltd recent earnings of $ expectations.